Table 2.
Weight change (Δ kg/6 months) in the immediate period (first 6-months) among people living with HIV from CNICS sites across the United States who initiated their first antiretroviral therapy regimen between 2012–2019 (n=3186) in adjusteda analyses (linear mixed models)
| Δ kg/6 months | 95% CI | P-value | ||
|---|---|---|---|---|
| Time on regimen (EFV reference) | 0.71 | −0.12 | 1.53 | 0.09 |
| Reg type x Time on regimen | ||||
| 1: RPV | −0.36 | −1.62 | 0.90 | 0.58 |
| 2: ATV | 2.15 | −0.01 | 4.30 | 0.051 |
| 3: DRV | 3.68 | 2.13 | 5.22 | <0.001 |
| 4: RAL | 2.06 | 0.11 | 4.01 | 0.04 |
| 5: EVG/TDF | 1.81 | 0.72 | 2.90 | <0.01 |
| 6: EVG/TAF | 1.88 | 0.61 | 3.16 | <0.01 |
| 7: DTG/TDF | 2.61 | 1.29 | 3.92 | <0.001 |
| 8: DTG/TAFb | 4.37 | 2.10 | 6.64 | <0.001 |
| 9: DTG/ABC | 2.28 | 1.06 | 3.49 | <0.001 |
| 10: BICc | 3.86 | 2.24 | 5.48 | <0.001 |
Abbreviations: CNICS: Centers for AIDS Research Network of Integrated Clinical Systems, EFV: efavirenz, RPV: rilpivirine, ATV: atazanavir, DRV; darunavir, RAL: raltegravir, EVG: elvitegravir, DTG: dolutegravir, BIC: bictegravir, TDF: tenofovir disoproxil fumarate, TAF: tenofovir alafenamide fumarate, ABC: abacavir
Model adjusted for time on regimen, regimen, age, sex, race/ethnicity, Hepatitis C, Hepatitis B, nadir CD4, smoking, diabetes, site, and antipsychotic medication use (time-updated)
DTG/TAF tested different using a Wald test vs EFV, RPV, EVG/TDF, EVG/TAF; DTG/ABC: p=0.08
BIC tested different using a Wald test vs EFV, RPV, EVG/TDF, EVG/TAF; DTG/ABC: p=0.06